144 related articles for article (PubMed ID: 38516779)
1. Association between monoclonal antibody therapy, vaccination, and longer-term symptom resolution after acute COVID-19.
Roberts SC; Jolley SE; Beaty LE; Aggarwal NR; Bennett TD; Carlson NE; Fish LE; Kwan BM; Russell S; Wogu AF; Wynia MA; Ginde AA
J Med Virol; 2024 Mar; 96(3):e29541. PubMed ID: 38516779
[TBL] [Abstract][Full Text] [Related]
2. Real-world effectiveness of COVID-19 vaccines and anti-SARS-CoV-2 monoclonal antibodies against postacute sequelae of SARS-CoV-2: analysis of a COVID-19 observational registry for a diverse US metropolitan population.
Tannous J; Pan AP; Potter T; Bako AT; Dlouhy K; Drews A; Sostman HD; Vahidy FS
BMJ Open; 2023 Apr; 13(4):e067611. PubMed ID: 37019490
[TBL] [Abstract][Full Text] [Related]
3. Monoclonal Antibodies for Treatment of SARS-CoV-2 Infection During Pregnancy : A Cohort Study.
McCreary EK; Lemon L; Megli C; Oakes A; Seymour CW;
Ann Intern Med; 2022 Dec; 175(12):1707-1715. PubMed ID: 36375150
[TBL] [Abstract][Full Text] [Related]
4. Association of Influenza Vaccination With SARS-CoV-2 Infection and Associated Hospitalization and Mortality Among Patients Aged 66 Years or Older.
Hosseini-Moghaddam SM; He S; Calzavara A; Campitelli MA; Kwong JC
JAMA Netw Open; 2022 Sep; 5(9):e2233730. PubMed ID: 36169955
[TBL] [Abstract][Full Text] [Related]
5. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study.
Antonelli M; Penfold RS; Merino J; Sudre CH; Molteni E; Berry S; Canas LS; Graham MS; Klaser K; Modat M; Murray B; Kerfoot E; Chen L; Deng J; Österdahl MF; Cheetham NJ; Drew DA; Nguyen LH; Pujol JC; Hu C; Selvachandran S; Polidori L; May A; Wolf J; Chan AT; Hammers A; Duncan EL; Spector TD; Ourselin S; Steves CJ
Lancet Infect Dis; 2022 Jan; 22(1):43-55. PubMed ID: 34480857
[TBL] [Abstract][Full Text] [Related]
6. Association between treatment failure and hospitalization after receipt of neutralizing monoclonal antibody treatment for COVID-19 outpatients.
Douin DJ; Wogu AF; Beaty LE; Carlson NE; Bennett TD; Aggarwal NR; Mayer DA; Ong TC; Russell S; Steele J; Peers JL; Molina KC; Wynia MK; Ginde AA
BMC Infect Dis; 2022 Nov; 22(1):818. PubMed ID: 36344927
[TBL] [Abstract][Full Text] [Related]
7. Evolving Real-World Effectiveness of Monoclonal Antibodies for Treatment of COVID-19 : A Cohort Study.
Kip KE; McCreary EK; Collins K; Minnier TE; Snyder GM; Garrard W; McKibben JC; Yealy DM; Seymour CW; Huang DT; Bariola JR; Schmidhofer M; Wadas RJ; Angus DC; Kip PL; Marroquin OC
Ann Intern Med; 2023 Apr; 176(4):496-504. PubMed ID: 37011399
[TBL] [Abstract][Full Text] [Related]
8. Timely course of SARS-CoV-2 infections and vaccinations in patients with hemato-oncological diseases: analysis of a real-life cohort.
Mair MJ; Mitterer M; Buratti T; Berchtold L; Fong D; Preusser M
ESMO Open; 2023 Jun; 8(3):101559. PubMed ID: 37196399
[TBL] [Abstract][Full Text] [Related]
9. Analysis of Rituximab Use, Time Between Rituximab and SARS-CoV-2 Vaccination, and COVID-19 Hospitalization or Death in Patients With Multiple Sclerosis.
Smith JB; Gonzales EG; Li BH; Langer-Gould A
JAMA Netw Open; 2022 Dec; 5(12):e2248664. PubMed ID: 36576740
[TBL] [Abstract][Full Text] [Related]
10. Longitudinal adaptive immune responses following sequential SARS-CoV-2 vaccinations in MS patients on anti-CD20 therapies and sphingosine-1-phosphate receptor modulators.
Sabatino JJ; Mittl K; Rowles W; Zamecnik CR; Loudermilk RP; Gerungan C; Spencer CM; Sagan SA; Alexander J; Mcpolin K; Chen P; Deshpande C; Wyse K; Maiese EM; Wilson MR; Zamvil SS; Bove R
Mult Scler Relat Disord; 2023 Feb; 70():104484. PubMed ID: 36608538
[TBL] [Abstract][Full Text] [Related]
11. Coverage and Estimated Effectiveness of mRNA COVID-19 Vaccines Among US Veterans.
Young-Xu Y; Korves C; Roberts J; Powell EI; Zwain GM; Smith J; Izurieta HS
JAMA Netw Open; 2021 Oct; 4(10):e2128391. PubMed ID: 34613401
[TBL] [Abstract][Full Text] [Related]
12. Risk and symptoms of COVID-19 in health professionals according to baseline immune status and booster vaccination during the Delta and Omicron waves in Switzerland-A multicentre cohort study.
Babouee Flury B; Güsewell S; Egger T; Leal O; Brucher A; Lemmenmeier E; Meier Kleeb D; Möller JC; Rieder P; Rütti M; Schmid HR; Stocker R; Vuichard-Gysin D; Wiggli B; Besold U; McGeer A; Risch L; Friedl A; Schlegel M; Kuster SP; Kahlert CR; Kohler P;
PLoS Med; 2022 Nov; 19(11):e1004125. PubMed ID: 36342956
[TBL] [Abstract][Full Text] [Related]
13. On variants and vaccines: The effectiveness of Covid-19 monoclonal antibody therapy during two distinct periods in the pandemic.
Srinivasan V; Weinstein SE; Bhimani A; Clemons NC; Dinolfo M; Shin CS; Grier J; Lopez A; Braggs J; Boucher J; Batiste QN; Garner OB; Yang S; Vijayan T
PLoS One; 2022; 17(12):e0278394. PubMed ID: 36454767
[TBL] [Abstract][Full Text] [Related]
14. Persistent COVID-19 Symptoms at 6 Months After Onset and the Role of Vaccination Before or After SARS-CoV-2 Infection.
Richard SA; Pollett SD; Fries AC; Berjohn CM; Maves RC; Lalani T; Smith AG; Mody RM; Ganesan A; Colombo RE; Lindholm DA; Morris MJ; Huprikar N; Colombo CJ; Madar C; Jones M; Larson DT; Bazan SE; Mende K; Saunders D; Livezey J; Lanteri CA; Scher AI; Byrne C; Rusiecki J; Ewers E; Epsi NJ; Rozman JS; English C; Simons MP; Tribble DR; Agan BK; Burgess TH;
JAMA Netw Open; 2023 Jan; 6(1):e2251360. PubMed ID: 36652247
[TBL] [Abstract][Full Text] [Related]
15. Factors Associated With Severe COVID-19 Among Vaccinated Adults Treated in US Veterans Affairs Hospitals.
Vo AD; La J; Wu JT; Strymish JM; Ronan M; Brophy M; Do NV; Branch-Elliman W; Fillmore NR; Monach PA
JAMA Netw Open; 2022 Oct; 5(10):e2240037. PubMed ID: 36264571
[TBL] [Abstract][Full Text] [Related]
16. Association between SARS-CoV-2 infection and select symptoms and conditions 31 to 150 days after testing among children and adults.
Zhang Y; Romieu-Hernandez A; Boehmer TK; Azziz-Baumgartner E; Carton TW; Gundlapalli AV; Fearrington J; Nagavedu K; Dea K; Moyneur E; Cowell LG; Kaushal R; Mayer KH; Puro J; Rasmussen SA; Thacker D; Weiner MG; Saydah S; Block JP;
BMC Infect Dis; 2024 Feb; 24(1):181. PubMed ID: 38341566
[TBL] [Abstract][Full Text] [Related]
17. Real-World Evidence of Neutralizing Monoclonal Antibodies for Preventing Hospitalization and Mortality in COVID-19 Outpatients.
Wynia MK; Beaty LE; Bennett TD; Carlson NE; Davis CB; Kwan BM; Mayer DA; Ong TC; Russell S; Steele JD; Stocker HR; Wogu AF; Zane RD; Sokol RJ; Ginde AA
Chest; 2023 May; 163(5):1061-1070. PubMed ID: 36441040
[TBL] [Abstract][Full Text] [Related]
18. SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19.
Hirsch C; Park YS; Piechotta V; Chai KL; Estcourt LJ; Monsef I; Salomon S; Wood EM; So-Osman C; McQuilten Z; Spinner CD; Malin JJ; Stegemann M; Skoetz N; Kreuzberger N
Cochrane Database Syst Rev; 2022 Jun; 6(6):CD014945. PubMed ID: 35713300
[TBL] [Abstract][Full Text] [Related]
19. Association between SARS-CoV-2 Infection and Select Symptoms and Conditions 31 to 150 Days After Testing among Children and Adults.
Zhang Y; Romieu-Hernandez A; Boehmer TK; Azziz-Baumgartner E; Carton TW; Gundlapalli AV; Fearrington J; Nagavedu K; Dea K; Moyneur E; Cowell LG; Kaushal R; Mayer KH; Puro J; Rasmussen SA; Thacker D; Weiner MG; Saydeh S; Block JP;
medRxiv; 2022 Dec; ():. PubMed ID: 36597540
[TBL] [Abstract][Full Text] [Related]
20. Use of complementary medicine and its association with SARS-CoV-2 vaccination during the COVID-19 pandemic: a longitudinal cohort study.
Nehme M; Braillard O; Rodondi PY; Guessous I
Swiss Med Wkly; 2023 Dec; 153():3505. PubMed ID: 38579302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
